Beam Therapeutics (BEAM) Operating Leases: 2019-2025
Historic Operating Leases for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $138.7 million.
- Beam Therapeutics' Operating Leases fell 6.97% to $138.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.7 million, marking a year-over-year decrease of 6.97%. This contributed to the annual value of $148.0 million for FY2024, which is 7.48% down from last year.
- Beam Therapeutics' Operating Leases amounted to $138.7 million in Q3 2025, which was down 2.20% from $141.9 million recorded in Q2 2025.
- Beam Therapeutics' Operating Leases' 5-year high stood at $168.6 million during Q4 2022, with a 5-year trough of $125.8 million in Q1 2021.
- In the last 3 years, Beam Therapeutics' Operating Leases had a median value of $152.6 million in 2024 and averaged $152.8 million.
- Its Operating Leases has fluctuated over the past 5 years, first soared by 459.09% in 2021, then decreased by 7.48% in 2024.
- Beam Therapeutics' Operating Leases (Quarterly) stood at $134.8 million in 2021, then grew by 25.08% to $168.6 million in 2022, then declined by 5.17% to $159.9 million in 2023, then decreased by 7.48% to $148.0 million in 2024, then declined by 6.97% to $138.7 million in 2025.
- Its last three reported values are $138.7 million in Q3 2025, $141.9 million for Q2 2025, and $144.9 million during Q1 2025.